Candel Therapeutics announced an oral presentation of CAN-2409 data at the ASCO Annual Meeting, focusing on prostate cancer treatment. Candel Therapeutics, Inc. announced the acceptance of an ...

announced that it will present updated data from its Phase 2 clinical trial ... at the 2025 ASCO Annual Meeting in Chicago. The presentation is scheduled for May 31, 2025. Vilastobart aims to ...

Awesome Tabular Deep Learning for "Representation Learning for Tabular Data: A Comprehensive Survey". If you use any content of this repo for your work, please cite the following bib entry: ...

The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection data on the company’s lead γ9δ2 ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

Users of the Internet generate 2.5 quintillion bytes of data each day, on average, according to recent research cites by Domo. The report was based on publicly available data from a range of sources, ...

“We are excited to share preclinical data on our therapeutic vaccine candidate, CLB-4000, with the Hepatitis B community,” said Aileen Rubio, PhD, CEO of ClearB Therapeutics. “Chronic ...

The presentation will focus on results from its ongoing open-label, randomized Phase I/II study EVICTION, including updated efficacy, safety and dose-selection data on the company's lead γ9δ2 T-cell ...

Results, highlighted in a poster presentation during the Predictive ... combined with methods for harmonizing diverse imaging data and the breadth of our training data. Onc.AI’s high-quality ...

Strasbourg, France, April 23, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will be ...

(AIM:FARN), a clinical-stage biopharmaceutical company developing novel immunotherapies, announces that new Phase II data from its ... of our results for an oral presentation also represents ...